PHARMORUBICIN has produced responses in a wide spectrum of neoplastic diseases and is indicated for the treatment of: breast cancer; gastric cancer; ovarian cancer; small cell lung cancer; lymphoma (non-Hodgkin's lymphoma); advanced/metastatic soft tissue sarcoma; superficial bladder cancer (Tis; Ta).
In bladder cancer, PHARMORUBICIN is also indicated in the prophylaxis of recurrence after transurethral resection of stage T1 papillary cancers and stage Ta multifocal papillary cancers (Grade 2 and 3).